Advanced Curriculum for
Multiple Sclerosis 2021
The 6th Annual Pre- ACTRIMS 2-Day, CME/CE Course
The Advanced Curriculum for Multiple Sclerosis 2021 virtual grand rounds experience is an innovative, comprehensive medical education program that delivers clinicians the best in science relative to all aspects of the MS disease spectrum. This two-day, virtual, interactive curriculum experience will utilize a longer-term patient case series to allow for in-depth clinical decision making on MS diagnostics, biomarkers, imaging, accurate differential diagnosis, first-line therapeutic, mitigation of adverse events, specific considerations for limiting disability, reducing progression, monitoring disease activity, switching therapies as needed, treating symptoms, managing special populations, and effectively utilizing the extended healthcare team.
Neurologists, MS specialists, fellows, residents, nurses, pharmacists, and other healthcare professionals involved in the management of patients with multiple sclerosis.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 14.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this live material for a maximum of 14.50 CNE Contact Hour (Provider Number P0491).
AcademicCME designates this continuing education activity for 14.50 CPE Contact Hours (1.45 CEUs) of continuing pharmacy education credit (JA4008190-0000-21-001-L04-P).
Supported by educational grants from Biogen; Bristol Myers Squibb Company; EMD Serono; Greenwich Biosciences, a GW Pharmaceuticals PLC Company and Sanofi
|Tuesday, February 23rd, 2021|
|Pre-Registration||Digital Self-Assessment Module I|
|7:45am – 8:00am EST||Welcome, Introduction, and Course Instruction
Course Director – Fred D. Lublin, MD
|8:00am – 9:00am EST||Advances in MS Science I
|9:00am – 10:00am EST||Case Presentation Series with Interactive Expert Panel – Brenda L. Banwell, MD; Tanuja Chitnis, MD; Andrew Goodman, MD; Jeffrey A. Cohen, MD|
|Patient A||17 Y/O F Diagnosed with Optic Neuritis, Abnormal MRI|
|Patient B||28 Y/O F with Symptoms Consistent with Relapsing-Remitting MS|
|Patient C||40 Y/O M with 10-Year History of Multiple Neurological Symptoms|
|Patient D||52 Y/O F with a 15-Year History of MS, Disease Actively Progressing|
|Patient E||65 Y/O M with Gradual Worsening Gait (never had a relapse)|
|Therapeutic Decision Making|
|10:00am – 12:00pm EST||Advances in MS Science II
|12:00pm – 1:00pm EST||Case Presentation Series with Interactive Expert Panel – Faculty: Brenda L. Banwell, MD; Tanuja Chitnis, MD; Andrew Goodman, MD; Jeffrey A. Cohen, MD|
|Patient A||17 Y/O F Diagnosed with MS, Initiating First-Line Therapy|
|Patient B||28 Y/O F Symptom Free on Treatment Now Pregnant|
|Patient C||40 Y/O M NMO, Considerations for Initiating Therapy|
|Patient D||52 Y/O F Advanced Therapeutic Decision-Making|
|Patient E||65 Y/O M Non-Ambulatory, Urinary Incontinence|
|1:00pm – 2:00 pm EST
2:00pm – 3:00pm EST
|The New and Emerging Role of Bruton’s Tyrosine Kinase Inhibitor (BTKi) Therapeutics to Improve Long-Term Outcomes in Patients with Relapsing Multiple Sclerosis
Benjamin M. Greenberg, MD; Aaron Miller, MD; Anthony Traboulsee, MD
*Supported by an independent educational grant from EMD Serono
A Scientific Analysis: The Long-Term Role for S1P Receptor (1,5) Modulator Therapeutics for the Effective Management of Patients with Relapsing MS
Mark S. Freedman, MD; Ilana Katz-Sand, MD; Clyde Markowitz, MD
*Supported by an independent educational grant from Bristol Myers Squibb Company
|Wednesday, February 24th, 2021|
|Optimizing Outcomes for MS Patients|
|8:00am – 9:30am EST||Advances in MS Science III
|Comprehensive MS Patient Care|
|9:30am – 11:00am EST||Advances in MS Science IV
|11:00am – 12:00pm EST||Case Presentation Series with Interactive Expert Panel – Brenda L. Banwell, MD; Tanuja Chitnis, MD; Andrew Goodman, MD; Jeffrey A. Cohen, MD|
|Patient A||17 Y/O F Relapse Free, Struggling in School, Reporting Emotional Distress|
|Patient B||28 Y/O F 3 Years Postpartum New Onset of Symptoms|
|Patient C||40 Y/O M Appears Stable, Assess Disease Progression|
|Patient D||52 Y/O F Continuing to Progress? Switch Therapies|
|Patient E||65 Y/O M Unchanged Symptoms Now with Poor Cognition|
|What Can We Do Better Moving Forward?|
|12:00pm – 1:00pm EST||Advances in MS Science V – Gary Cutter, MS, PhD; Anne Cross, MD
|1:00pm – 2:00pm EST
2:00pm – 3:00pm EST
|Applying New Science to Symptom Management Across the Spectrum of Multiple Sclerosis
Francois Bethoux MD; Stephen Krieger, MD; Amy Perrin Ross, APN, MSN, CNRN, MSCN
*Supported by an independent educational grant from Greenwich Biosciences, a GW Pharmaceuticals PLC Company
Applying New Science to Patient-Focused Treatment Strategies Across the Spectrum of Multiple Sclerosis
Patricia Coyle, MD; June Halper, MSN, APN-C, MSCN; Clyde Markowitz, MD
*Supported by an independent educational grant from Biogen
Americans with Disabilities Act
Event Staff will be glad to assist you with any questions or special needs. Please contact AcademicCME at [email protected] or 610-687-3300.
Further details regarding how to join the virtual sessions will be emailed to the address used to register prior to the event. Feel free to also follow us on Twitter @academiccme for real-time updates and information.
This activity is being held in conjunction with the ACTRIMS Forum 2021, brought to you virtually from Thursday, February 25th to Saturday, February 27th, 2021. For more information and to register for the forum, please visit: https://forum.actrims.org/